CN103796644B - 芳香酶抑制剂用于治疗性腺功能减退和相关疾病的用途 - Google Patents

芳香酶抑制剂用于治疗性腺功能减退和相关疾病的用途 Download PDF

Info

Publication number
CN103796644B
CN103796644B CN201280043378.9A CN201280043378A CN103796644B CN 103796644 B CN103796644 B CN 103796644B CN 201280043378 A CN201280043378 A CN 201280043378A CN 103796644 B CN103796644 B CN 103796644B
Authority
CN
China
Prior art keywords
compound
fluoro
methylene
bisbenzonitrile
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280043378.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN103796644A (zh
Inventor
A·泰勒
L·B·克里克斯坦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46846026&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN103796644(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN103796644A publication Critical patent/CN103796644A/zh
Application granted granted Critical
Publication of CN103796644B publication Critical patent/CN103796644B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201280043378.9A 2011-09-08 2012-09-06 芳香酶抑制剂用于治疗性腺功能减退和相关疾病的用途 Active CN103796644B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161532459P 2011-09-08 2011-09-08
US61/532,459 2011-09-08
US201261638588P 2012-04-26 2012-04-26
US61/638,588 2012-04-26
PCT/US2012/053844 WO2013036562A1 (en) 2011-09-08 2012-09-06 Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases

Publications (2)

Publication Number Publication Date
CN103796644A CN103796644A (zh) 2014-05-14
CN103796644B true CN103796644B (zh) 2017-05-03

Family

ID=46846026

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280043378.9A Active CN103796644B (zh) 2011-09-08 2012-09-06 芳香酶抑制剂用于治疗性腺功能减退和相关疾病的用途
CN201280043614.7A Active CN103781476B (zh) 2011-09-08 2012-09-06 包含芳香酶抑制剂的药物组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280043614.7A Active CN103781476B (zh) 2011-09-08 2012-09-06 包含芳香酶抑制剂的药物组合物

Country Status (31)

Country Link
US (4) US9295668B2 (enExample)
EP (2) EP2753313B1 (enExample)
JP (2) JP6051467B2 (enExample)
KR (3) KR20140071358A (enExample)
CN (2) CN103796644B (enExample)
AR (1) AR087790A1 (enExample)
AU (2) AU2012304694B2 (enExample)
BR (2) BR112014005434B1 (enExample)
CA (2) CA2846884C (enExample)
CL (1) CL2014000552A1 (enExample)
CY (2) CY1118461T1 (enExample)
DK (2) DK2753312T3 (enExample)
ES (2) ES2613667T3 (enExample)
HR (2) HRP20170003T1 (enExample)
HU (2) HUE031478T2 (enExample)
IL (1) IL231234A (enExample)
IN (1) IN2014DN01619A (enExample)
LT (2) LT2753312T (enExample)
MX (2) MX343902B (enExample)
PE (1) PE20141584A1 (enExample)
PH (1) PH12014500435A1 (enExample)
PL (2) PL2753313T3 (enExample)
PT (2) PT2753313T (enExample)
RU (2) RU2617510C2 (enExample)
SG (2) SG2014012132A (enExample)
SI (2) SI2753312T1 (enExample)
TN (1) TN2014000059A1 (enExample)
TW (1) TW201316987A (enExample)
UY (1) UY34315A (enExample)
WO (2) WO2013036562A1 (enExample)
ZA (1) ZA201401040B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2753312T1 (sl) * 2011-09-08 2017-10-30 Mereo Biopharma 2 Limited Uporaba inhibitorja aromataze za zdravljenje hipogonadizma in sororodnih bolezni
WO2015148549A1 (en) * 2014-03-26 2015-10-01 The Regents Of The University Of California Ultrasensitive androgen receptor bioassay
PT3166596T (pt) * 2014-07-07 2018-10-19 Novartis Ag Formas farmacêuticas
GB201614179D0 (en) * 2016-08-19 2016-10-05 Mereo Biopharma 2 Ltd Dosage regimen for the treatment of endometriosis
JP2020510027A (ja) * 2017-03-08 2020-04-02 アリアド ファーマシューティカルズ，インコーポレーテッド ５−クロロ−ｎ４−［２−（ジメチルホスホリル）フェニル］−ｎ２−｛２−メトキシ−４−［４−（４−メチルピペラジン−１−イル）ピペリジン−１−イル］フェニル｝ピリミジン−２，４−ジアミンを含む医薬製剤
CA3078652A1 (en) 2017-10-12 2019-04-18 Novo Nordisk A/S Semaglutide in medical therapy
USD894149S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment
USD894148S1 (en) * 2018-08-16 2020-08-25 Alibaba Group Holding Limited Information terminal for payment
JP7121999B2 (ja) * 2019-09-26 2022-08-19 学校法人九州文化学園 男性性腺機能低下症治療剤
US12552754B1 (en) 2025-06-11 2026-02-17 ReproNovo SA Leflutrozole compositions of matter and processes for preparation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009057A1 (de) * 1994-09-22 1996-03-28 Schering Aktiengesellschaft Verwendung von aromatasehemmern zur herstellung eines arzneimittels zur behandlung eines relativen androgenmangels beim mann
US5637605A (en) * 1990-12-12 1997-06-10 Ciba Geigy Corporation α-fluoro-α-1-(1,2,4-triazolyl)-phenylmethyl derivatives useful as aromatase inhibitors
CN1281361A (zh) * 1997-12-12 2001-01-24 霍莫斯医疗有限公司 芳香酶抑制剂治疗泌尿疾病的用途和研究泌尿疾病的方法
WO2002002113A1 (en) * 2000-07-05 2002-01-10 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition
WO2003082254A1 (en) * 2002-04-03 2003-10-09 Jencap Research Ltd. Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male
CN1549734A (zh) * 2001-04-17 2004-11-24 ����˹ó�׹ɷ����޹�˾ 增强辅助生殖的芳香酶抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749713A (en) 1986-03-07 1988-06-07 Ciba-Geigy Corporation Alpha-heterocycle substituted tolunitriles
US7101573B2 (en) * 2001-09-28 2006-09-05 Mcneil-Pcc, Inc. Simethicone solid oral dosage form
WO2006114702A2 (en) 2005-04-25 2006-11-02 Pfizer Products Inc. Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
CN102335219A (zh) * 2007-11-21 2012-02-01 客乐谐制药株式会社 芳香酶抑制剂
SI2753312T1 (sl) * 2011-09-08 2017-10-30 Mereo Biopharma 2 Limited Uporaba inhibitorja aromataze za zdravljenje hipogonadizma in sororodnih bolezni

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5637605A (en) * 1990-12-12 1997-06-10 Ciba Geigy Corporation α-fluoro-α-1-(1,2,4-triazolyl)-phenylmethyl derivatives useful as aromatase inhibitors
WO1996009057A1 (de) * 1994-09-22 1996-03-28 Schering Aktiengesellschaft Verwendung von aromatasehemmern zur herstellung eines arzneimittels zur behandlung eines relativen androgenmangels beim mann
CN1281361A (zh) * 1997-12-12 2001-01-24 霍莫斯医疗有限公司 芳香酶抑制剂治疗泌尿疾病的用途和研究泌尿疾病的方法
WO2002002113A1 (en) * 2000-07-05 2002-01-10 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and letrozole for providing an anit-androgenic effect and aromatase inhibition
CN1549734A (zh) * 2001-04-17 2004-11-24 ����˹ó�׹ɷ����޹�˾ 增强辅助生殖的芳香酶抑制剂
WO2003082254A1 (en) * 2002-04-03 2003-10-09 Jencap Research Ltd. Pharmaceutical composition comprising an aromatase inhibitor and an estrogen suitable for hormone replacement therapy for a male

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Effect of Estrogen Deprivation on the Reproductive Physiology of Male and Female Primates;Gunapala Shetty etal.;《J. Steroid Biochem. Molec. Biol.》;19971231;第61卷(第3-6期);第157-166页 *
Effect of long-term treatment with aromatase inhibitor on testicular function of adult male bonnet monkeys (M. radiata);Gunapala Shetty et al.;《Steroids》;19980831;第63卷;第414–420页，尤其摘要，第415页右栏第5段，第416页图1 *
Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism;H. de Boer et al.;《Diabetes, Obesity and Metabolism》;20051231;第7卷;第211-215页，尤其摘要，第212页右栏第3-4段 *
STRUCTURE-ACTIVITY RELATIONSHIPS AND BINDING MODEL OF NOVEL AROMATASE INHIBITORS;M. LANG et al.;《J. Steroid Biochem. Molec. Biol》;19931231;第44卷(第4-6期);第421-428页，尤其摘要 *

Also Published As

Publication number Publication date
JP6280501B2 (ja) 2018-02-14
US20140213622A1 (en) 2014-07-31
PT2753312T (pt) 2017-02-03
US20140309267A1 (en) 2014-10-16
DK2753313T3 (en) 2017-02-13
AU2012304694A1 (en) 2014-03-20
HRP20170003T1 (hr) 2017-03-10
US9295668B2 (en) 2016-03-29
LT2753312T (lt) 2017-01-25
CY1118461T1 (el) 2017-07-12
ZA201401040B (en) 2015-12-23
CL2014000552A1 (es) 2014-09-12
CA2846884C (en) 2019-04-09
CA2845929A1 (en) 2013-03-14
SG2014012132A (en) 2014-06-27
BR112014004879A2 (pt) 2017-03-14
TW201316987A (zh) 2013-05-01
JP2014526465A (ja) 2014-10-06
RU2014113334A (ru) 2015-10-20
PH12014500435A1 (en) 2019-03-22
RU2014113575A (ru) 2015-10-20
EP2753312A1 (en) 2014-07-16
DK2753312T3 (da) 2017-02-13
CN103796644A (zh) 2014-05-14
US9370505B2 (en) 2016-06-21
CY1118499T1 (el) 2017-07-12
WO2013036562A1 (en) 2013-03-14
IL231234A0 (en) 2014-04-30
WO2013036563A1 (en) 2013-03-14
AU2012304694B2 (en) 2016-04-07
SG10201607503WA (en) 2016-10-28
AU2012304693A1 (en) 2014-03-13
BR112014005434B1 (pt) 2021-01-05
US20160346257A1 (en) 2016-12-01
KR101872561B1 (ko) 2018-06-28
PT2753313T (pt) 2017-02-02
IL231234A (en) 2016-12-29
CN103781476A (zh) 2014-05-07
RU2628808C2 (ru) 2017-08-22
CA2845929C (en) 2018-06-19
LT2753313T (lt) 2017-02-10
SI2753312T1 (sl) 2017-10-30
IN2014DN01619A (enExample) 2015-05-15
US10064844B2 (en) 2018-09-04
JP6051467B2 (ja) 2016-12-27
PL2753313T3 (pl) 2017-07-31
HRP20170002T1 (hr) 2017-02-24
EP2753312B1 (en) 2016-12-14
MX360315B (es) 2018-10-29
KR20140071358A (ko) 2014-06-11
AR087790A1 (es) 2014-04-16
US9750724B2 (en) 2017-09-05
ES2613667T3 (es) 2017-05-25
HUE031478T2 (hu) 2017-07-28
ES2613666T3 (es) 2017-05-25
JP2014528932A (ja) 2014-10-30
MX2014002773A (es) 2014-06-05
CA2846884A1 (en) 2013-03-14
BR112014005434A2 (pt) 2017-04-04
MX343902B (es) 2016-11-28
RU2617510C2 (ru) 2017-04-25
KR20140058619A (ko) 2014-05-14
MX2014002780A (es) 2014-06-05
NZ621476A (en) 2016-02-26
PE20141584A1 (es) 2014-11-13
HUE031435T2 (en) 2017-07-28
BR112014004879B1 (pt) 2020-01-28
US20160243084A1 (en) 2016-08-25
EP2753313B1 (en) 2016-12-14
EP2753313A1 (en) 2014-07-16
CN103781476B (zh) 2016-12-07
UY34315A (es) 2013-04-30
TN2014000059A1 (en) 2015-07-01
SI2753313T1 (sl) 2017-04-26
AU2012304693B2 (en) 2016-03-31
KR20180030254A (ko) 2018-03-21
PL2753312T3 (pl) 2017-06-30

Similar Documents

Publication Publication Date Title
CN103796644A (zh) 芳香酶抑制剂用于治疗性腺功能减退和相关疾病的用途
US20190175615A1 (en) Lipobalanced long chain testosterone esters for oral delivery
Chao et al. Male contraception
US20190240235A1 (en) Lipobalanced long chain testosterone esters for oral delivery
EP2968363B1 (en) Lipobalanced long chain testosterone esters for oral delivery
JP2006522833A (ja) エストロゲンおよびプロゲスチンの投与法
JP2019524846A (ja) 子宮内膜症の治療のための投与レジメン
HK1196256A (en) Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases
HK1196256B (en) Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases
NZ621476B2 (en) Use of an aromatase inhibitor for the treatment of hypogonadism and related diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant